1. Scrip
  2. >>Business

From Witty To Walmsley – The Priorities For GSK's New CEO

 
• By Sukaina Virji

It's Emma Walmsley's first week at the helm of GlaxoSmithKline. What can we expect in terms of her priorities?

Emma Walmsley GSK
GSK CEO Emma Walmsley

When Emma Walmsley was revealed as the successor to Sir Andrew Witty as CEO of GlaxoSmithKline PLC, it was clear the board had opted to secure Witty's volume-first growth strategy for the company that was launched in 2015.

But the world looks quite different in 2017 than it did in 2015

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Business

More from Scrip

Lilly Builds Obesity Momentum With New SURMOUNT Data Besting Novo Nordisk

 
• By Alaric DeArment

The presentation and publication of the Phase IIIb study showing greater efficacy for Zepbound over Wegovy come at a time when competition has been heating up between the two obesity medications.

Trump’s MFN Executive Order More Rhetoric Than Action

 
• By Jessica Merrill

The details of Trump’s latest executive order on drug pricing are vague and the president put more blame on other countries and pharma distributors than drug companies.

Biopharma Deals ROI Has Fallen And Market Instability Could Make It Worse

 
• By Andrew McConaghie

Rising biotech valuations mean return on investment on some deals is non-existent for big pharma, though certain strategies will improve chances of success, a new analysis has found.